


## Summary

<b>Name</b>	VSIG4
<b>Purity</b>	Greater than 95% as determined by reducing SDS-PAGE
<b>Endotoxin level</b>	<1 EU/μg as determined by LAL test.
<b>Construction</b>	Recombinant Mouse V-Set And Ig Domain-Containing Protein 4 is produced by our Mammalian expression system and the target gene encoding His20-Pro187 is expressed with a 6His tag at the C-terminus.
<b>Accession #</b>	F6TUL9
<b>Host</b>	Human Cells
<b>Species</b>	Mouse
<b>Predicted Molecular Mass</b>	19.7 KDa
<b>Formulation</b>	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
<b>Stability&amp;Storage</b>	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
<b>Reconstitution</b>	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

## SDS-PAGE image



## Background

**Product Name: Recombinant Mouse VSIG4 (C-6His)**  
**Catalog #: PHM1826**



---

**Alternative Names**

Vsig4;V-set and immunoglobulin domain containing 4;

**Background**

V-set and immunoglobulin domain containing 4 (VSIG4) is a type I transmembrane glycoprotein that is a B7 family-related protein and an Ig superfamily member. Mouse VSIG4 is synthesized as a 280 amino acid (aa) precursor that contains a signal sequence, an IgV-type immunological domain (aa 36-115), one potential N-linked glycosylation site, and a single transmembrane domain. The IgV domain of mouse VSIG4 shares 86% and 80% aa sequence identity with the IgV domains of rat and human VSIG4, respectively. VSIG4 functions as a negative regulator of mouse as well as human T cell activation, and may be involved in the maintenance of peripheral T cell tolerance and/or unresponsiveness. VSIG4 acts as a macrophage complement receptor by binding complement fragments C3b and iC3b. VSIG4 binding to C3b inhibits complement activation through the alternative pathway, making it a potent suppressor of established inflammation.

**Note**

For Research Use Only , Not for Diagnostic Use.